197 related articles for article (PubMed ID: 24154489)
1. Characterization of vemurafenib phototoxicity in a mouse model.
Boudon SM; Plappert-Helbig U; Odermatt A; Bauer D
Toxicol Sci; 2014 Jan; 137(1):259-67. PubMed ID: 24154489
[TBL] [Abstract][Full Text] [Related]
2. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B
Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib: an unusual UVA-induced photosensitivity.
Gelot P; Dutartre H; Khammari A; Boisrobert A; Schmitt C; Deybach JC; Nguyen JM; Seité S; Dréno B
Exp Dermatol; 2013 Apr; 22(4):297-8. PubMed ID: 23528218
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease.
Brugière C; Stefan A; Morice C; Cornet E; Moreau A; Allouche S; Verneuil L
Br J Dermatol; 2014 Dec; 171(6):1529-32. PubMed ID: 25066094
[TBL] [Abstract][Full Text] [Related]
5. The phototoxicity of vemurafenib: An investigation of clinical monochromator phototesting and in vitro phototoxicity testing.
Woods JA; Ferguson JS; Kalra S; Degabriele A; Gardner J; Logan P; Ferguson J
J Photochem Photobiol B; 2015 Oct; 151():233-8. PubMed ID: 26318280
[TBL] [Abstract][Full Text] [Related]
6. Interplay Between Membrane Lipid Peroxidation and Photoproduct Formation in the Ultraviolet A-Induced Phototoxicity of Vemurafenib in Skin Keratinocytes.
Teixeira A; Morlière P; Ferreira J; Conte MA; Galmiche A; Mazière JC; Santus R; Filipe P
Toxicol Sci; 2016 Dec; 154(2):289-295. PubMed ID: 27566444
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of the phototoxicity induced by BRAF inhibitors and alleviation through antioxidants.
Heppt MV; Clanner-Engelshofen BM; Marsela E; Wessely A; Kammerbauer C; Przybilla B; French LE; Berking C; Reinholz M
Photodermatol Photoimmunol Photomed; 2020 Mar; 36(2):126-134. PubMed ID: 31618797
[TBL] [Abstract][Full Text] [Related]
8. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.
Grippo JF; Zhang W; Heinzmann D; Yang KH; Wong J; Joe AK; Munster P; Sarapa N; Daud A
Cancer Chemother Pharmacol; 2014 Jan; 73(1):103-11. PubMed ID: 24178368
[TBL] [Abstract][Full Text] [Related]
9. Phototoxicity of bituminous tars-correspondence between results of 3T3 NRU PT, 3D skin model and experimental human data.
Jirová D; Kejlová K; Bendová H; Ditrichová D; Mezulániková M
Toxicol In Vitro; 2005 Oct; 19(7):931-4. PubMed ID: 16061351
[TBL] [Abstract][Full Text] [Related]
10. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
Ribas A; Zhang W; Chang I; Shirai K; Ernstoff MS; Daud A; Cowey CL; Daniels G; Seja E; O'Laco E; Glaspy JA; Chmielowski B; Hill T; Joe AK; Grippo JF
J Clin Pharmacol; 2014 Apr; 54(4):368-74. PubMed ID: 24374975
[TBL] [Abstract][Full Text] [Related]
11. In vitro photosafety and efficacy screening of apigenin, chrysin and beta-carotene for UVA and VIS protection.
Freitas JV; Gaspar LR
Eur J Pharm Sci; 2016 Jun; 89():146-53. PubMed ID: 27130544
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
13. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of skin phototoxicity study using SD rats by transdermal and oral administration.
Yonezawa Y; Ohsumi T; Miyashita T; Kataoka A; Hashimoto K; Nejishima H; Ogawa H
J Toxicol Sci; 2015 Dec; 40(6):667-83. PubMed ID: 26558448
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the phototoxic potential of plants used in oriental medicine.
Bark KM; Heo EP; Han KD; Kim MB; Lee ST; Gil EM; Kim TH
J Ethnopharmacol; 2010 Jan; 127(1):11-8. PubMed ID: 19818392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
